HL7.TERMINOLOGY\Substance Admin Substitution

HL7 Terminology (THO)
5.0.0 - Publication International flag

This page is part of the HL7 Terminology (v5.0.0: Release) based on FHIR R4. The current version which supercedes this version is 5.2.0. For a full list of available versions, see the Directory of published versions

CodeSystem: Substance Admin Substitution

Official URL: http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution		Version: 2.1.0
Active as of 2019-03-20	Responsible: Health Level 7	Computable Name: SubstanceAdminSubstitution
Other Identifiers: : urn:oid:2.16.840.1.113883.5.1070

Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.

This Code system is referenced in the content logical definition of the following value sets:

Properties

Code

URL

Type

Description

Specializes

Coding

The child code is a more narrow version of the concept represented by the parent code. I.e. Every child concept is also a valid parent concept. Used to allow determination of subsumption. Must be transitive, irreflexive, antisymmetric.

Generalizes

Coding

Inverse of Specializes. Only included as a derived relationship.

internalId

http://terminology.hl7.org/CodeSystem/utg-concept-properties#v3-internal-id

code

The internal identifier for the concept in the HL7 Access database repository.

notSelectable

http://hl7.org/fhir/concept-properties#notSelectable

boolean

Indicates that the code is abstract - only intended to be used as a selector for other concepts

status

http://hl7.org/fhir/concept-properties#status

code

Designation of a concept's state. Normally is not populated unless the state is retired.

This code system http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution defines the following codes:

Lvl	Code	Display	Definition	internalId	Not Selectable	status
1	_ActSubstanceAdminSubstitutionCode	ActSubstanceAdminSubstitutionCode	Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.	21284	true	active
2	E	equivalent	Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.	23107		active
3	EC	equivalent composition	Description: Substitution occurred or is permitted with another product that is a: * pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester * pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: * Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate * Pharmaceutical equivalent: Lisonpril for Zestril	23108		active
4	BC	brand composition	Description: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: * Zestril for Prinivil * Coumadin for Jantoven	23109		active
4	G	generic composition	Description: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: * Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)	16623		active
3	TE	therapeutic alternative	Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: * ranitidine for Tagamet	16624		active
4	TB	therapeutic brand	Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics > Examples: * Zantac for Tagamet	23105		active
4	TG	therapeutic generic	Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands > Examples: * Ranitidine for cimetidine	23106		active
2	F	formulary	Description: This substitution was performed or is permitted based on formulary guidelines.	16625		active
2	N	none	No substitution occurred or is permitted.	16622		active